Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Offer Update

12 Sep 2008 16:43

RNS Number : 3754D
Braveheart Investment Group plc
12 September 2008
 



For release: 12 September 2008

 

Braveheart Investment Group plc 

("Braveheart" or the "Group")

 Update on Offer 

Braveheart announces that further to the Group's announcement on 18th July 2008, relating to a possible offer by Braveheart for ANGLE plc ("ANGLE"), the Board of Braveheart has reviewed its options and can confirm it is no longer considering making an offer for ANGLE.

For the purposes of Rule 2.8 and other relevant provisions of The City Code on Takeovers and Mergers ('City Code'), Braveheart reserves the right to announce an offer or possible offer or make or participate in an offer or possible offer for ANGLE (including the right to make or announce or participate in an offer or possible offer at any price or on any terms whatsoever) and/or take any other action which would otherwise be restricted under Rule 2.8 of the City Code at any time within the next six months in the event that:

 

(i) an agreement or recommendation from the Board of ANGLE is forthcoming; or 

 

(ii) there is an announcement by a third party of a firm intention to make an offer for ANGLE; or

 

(iii) ANGLE announces a whitewash proposal (as described in note 1 of the Notes on Dispensations from Rule 9 of the City Code) or a reverse takeover (as described in note 2 on Rule 3.2 of the City Code); or

 

(iv) there is a material change in circumstances.

For further information please contact: 

 

Noble & Company Limited

David Ovens, Director Tel: 0131 225 9677

Seymour Pierce Limited (nomad/broker to Braveheart)

Jeremy Garrett-Cox, Director  Tel: 020 7107 8000

 

Tavistock Communications

Simon Hudson / Clemmie Carr Tel: 020 7920 3150

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPFKBKNPBKDCCD
Date   Source Headline
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.